We examined the effects of ten fluoroquinolone antibacterial agents, levofloxacin, sitafloxacin, trovafloxacin, ciprofloxacin, gemifloxacin, tosufloxacin, gatifloxacin, grepafloxacin, moxifloxacin and sparfloxacin, on action potentials recorded from guinea pig ventricular myocardia. Sparfloxacin prolonged action potential duration (APD) by about 8% at 10 mM and 41% at 100 mM. Gatifloxacin, grepafloxacin and moxifloxacin also prolonged APD at 100 m M by about 13%, 24% and 25%, respectively. In contrast, levofloxacin, sitafloxacin, trovafloxacin, ciprofloxacin, gemifloxacin and tosufloxacin had little or no APD-prolonging effect at concentrations as high as 100 mM. These findings suggest that there are differences in potency to prolong QT interval among the fluoroquinolones.
Recently, numerous cases of electrocardiographic QT interval prolongation and subsequent fatal polymorphic ventricular tachycardia termed torsades de pointes (TdP) related to treatment with non-cardiovascular drugs have been reported (1) . Concerning antibacterial agents, macrolides, notably erythromycin, have been reported to induce QT interval prolongation. In the case of fluoroquinolone antibacterial agents, prolongation of the rate-corrected QT interval (QTc) was initially highlighted by the effects observed with sparfloxacin (2 -4) . Sparfloxacin was shown to prolong cardiac repolarization and induce early afterdepolarizations in rabbit Purkinje fibers (5) . In 1999, grepafloxacin, a fluoroquinolone, was withdrawn voluntarily from the US market due to the QT phenomena. Consequently, QT prolongation is often referred to as "a class effect" of all fluoroquinolones by reason of the QT phenomena caused by some fluoroquinolones (6) . However, there are few electrophysiological data available to assess whether all fluoroquinolones have the potency to provoke QT prolongation and subsequent TdP.
Among electrocardiographic measures, the QT interval is markedly affected by heart rate. Although the QTc calculated by Bazett's formula has been used as a routine procedure to correct QT for changes in heart rate, it can not completely eliminate the influence of heart rate. The comparison of the QT intervals measured at different heart rate might lead to a false hypothesis. The most reliable method to assess the QT intervals is to measure those at fixed heart rates (7) .
In the present study, we assessed the effects of 10 fluoroquinolones on the cardiac repolarization by measuring the action potentials recorded from isolated guinea pig right ventricular myocardia under constant conditions, namely, myocardial preparations were electrically stimulated at the fixed pacing frequency of 1 Hz.
All experimental procedures were performed in accordance with the in-house guidelines of the Institutional Animal Care and Use Committee of Daiichi Pharmaceutical Co., Ltd. Male Hartley guinea pigs, weighing 347 to 957 g, were sacrificed. Tissue strips dissected from the right ventricular free wall were mounted horizontally in organ baths containing Krebs-Henseleit solution of the following composition: 118 mM NaCl, 4.7 mM KCl, 25.0 mM NaH2PO4, 1.2 mM MgSO4, 1.2 mM NaH2CO3, 2.5 mM CaCl2 and 11 mM D-glucose, maintained at 36.5 ± 0.5°C and aerated with a mixture of 95% O2 + 5% CO2. The strips were electrically driven using rectangular pulses (1-ms duration with a frequency of 1 Hz and an intensity 1.3 times the diastolic threshold) via bipolar platinum electrodes. Transmembrane action potentials were recorded using conventional glass microelectrodes filled with 3 M KCl (tip resistance of 5 -30 MW) connected to a microelectrode amplifier (MEZ-8300; Nihon Kohden, Tokyo). Glass micro-electrodes were penetrated through the endocardial side of tissue preparations. After a stabilization period of at least 1 h, 2, 18 and 180 mL of the 10 mM stock solution of test compounds were cumulatively added to the 20 mL bathing solution (final concentrations of the test compounds: 1, 10 and 100 mM). The vehicle control groups also cumulatively received 2, 18 and 180 m L of 45% dimethyl sulfoxide (DMSO) or 1% lactate solution (final concentrations of DMSO were 0.0045%, 0.045% and 0.45%, and lactate were 0.0001%, 0.001% and 0.01%, respectively).
Transmembrane action potentials were recorded prior to and 30 min after exposure to each concentration of the drugs. The parameters of the action potentials analyzed by a computer system were: resting membrane potential, action potential amplitude, overshoot, action potential duration at 20%, 50% and 90% repolarization (APD20, APD50 and APD90) and maximum rate of rise of action potential (dV /dt max).
Differences in cardiac action potential parameters between pre-and post-exposure of the vehicle control group were analyzed by the paired t-test. Differences in the cardiac action potential parameters between the DMSOtreated and lactate-treated groups analyzed by Student's t-test were not significant. Therefore, the pooled samples of the DMSO and lactate-solution-treated groups served as the vehicle control group. Differences in the cardiac action potential parameters between the vehicle control group and fluoroquinolone-treated groups were analyzed by Dunnett's test at each concentration. A value of P<0.05 was considered significant.
The fluoroquinolone antibacterial agents were obtained as follows: sparfloxacin was extracted from a commercial product (Spara ® ; Dainippon Pharmaceuticals, Osaka), and the other fluoroquinolones were synthesized at Daiichi Pharmaceutical, Co., Ltd. (Tokyo). Ten millimolar stock solutions of each fluoroquinolone were prepared as follows. Gatifloxacin and sparfloxacin were dissolved in DMSO, followed by dilution with Krebs-Henseleit solution (the concentration of DMSO in the stock solution: 45% (v/ v)). Levofloxacin was dissolved in physiological saline; sitafloxacin, in saline (pH 4.0); trovafloxacin, ciprofloxacin and gemifloxacin, in 1% (w/ v) lactate solution; grepafloxacin and moxifloxacin, in distilled water, and tosufloxacin, in 0.1 N NaOH solution. Figure 1 shows the effects of 10 fluoroquinolones on APD 90 at concentrations of 0 -100 mM. Figure 2 demonstrated the individual percent changes in APD 90 from the initial value at 100 mM of 10 fluoroquinolones.
The vehicle control group caused significant but negligible changes in resting membrane potential (+0.5 mV, P = 0.0293) and action potential amplitude (-1.1 mV, P = 0.0106) at the highest concentration from initial values, while there was no change in other parameters including APD at any concentrations.
At 1 mM, none of the fluoroquinolones evoked any changes in the cardiac action potential parameters except sitafloxacin. Sitafloxacin showed significant but extremely slight increase (+1.0 mV, P = 0.0310) in overshoot at only 1 m M. Since this phenomenon evoked by sitafloxacin was not observed at 10 and 100 m M, it was not considered to be pharmacologically significant. At 10 m M, only sparfloxacin prolonged APD90 (8.4%, P = 0.0024) and APD50 (9.0%, P = 0.0324). At 100 mM, each drug prolonged APD as follows: gatifloxacin, APD90 (12.7%, P = 0.0074) and APD50 (13.9%, P = 0.0288); grepafloxacin, APD90 (23.8%, P<0.0001), APD50 (24.0%, P<0.0001) and APD20 (17.8%, P = 0.0379); moxifloxacin, APD90 (25.1%, P<0.0001) and APD50 (25.2%, P<0.0001); sparfloxacin, APD90 (40.8%, P<0.0001) and APD50 (40.3%, P<0.0001). Additionally, sparfloxacin decreased overshoot (-10.7%, P = 0.0223). In contrast, levofloxacin, sitafloxacin, ciprofloxacin and gemifloxacin did not induce any changes in the cardiac action potential parameters at concentrations up to 100 mM. With regard to APD90, the changes induced by levofloxacin (0.8%), sitafloxacin (2.4%), trovafloxacin (2.9%), ciprofloxacin (3.3%), gemifloxacin (4.2%) and tosufloxacin (5.2%) were minor, although there were some preparations showing about 8% to 9% prolongation in the ciprofloxacin, gemifloxacin and tosufloxacin-treated groups beyond the range of the vehicle control group (-6.1% to 5.2%).
In the present study, particularly, levofloxacin induced no in vitro cardiac electrophysiological effects even at concentrations as high as 100 mM, which corresponds to approximately 10 times higher than the effective clinical plasma concentrations. This finding about levofloxacin is consistent with the results in rabbit Purkinje fiber (5) . Concerning levofloxacin treatment, extremely rare cases of TdP or QT prolongation have been reported, namely, 12 cases per 150 million prescriptions throughout the world (post-marketing surveillance data of Daiichi Pharmaceutical), and the causal relationships between those cases and levofloxacin are uncertain. In contrast, sparfloxacin at 10 mM or gatifloxacin, grepafloxacin and moxifloxacin at 100 mM prolonged APD markedly. These findings may account for the QT phenomena provoked by most of those fluoroquinolones in clinical use. Namely, grepafloxacin, moxifloxacin or sparfloxacin were reported to cause the QTc interval prolongation or death from arrhythmia in humans when orally administered (8) . Additionally, oral administration of 60 mg /kg of sparfloxacin, but not levofloxacin, caused TdP leading to ventricular fibrillation in the chronic complete atrioventricular block dogs (9) . Most of the drugs that induce QT prolongation have been reported to share the same ability to block the rapid component of the delayed rectifier K + current (IKr) encoded by the human ether-à-go-go-related gene (HERG) K + channel (1). Blockade of IKr leads to a delay in the cardiac repolarization and prolongs the APD of myocardia and consequently prolongs the QT interval on ECG. On this point, sparfloxacin, moxifloxacin, gatifloxacin, grepafloxacin, levofloxacin, ciprofloxacin or ofloxacin have been reported to have IKr-blocking ability (10 -12) . Though there are differences in absolute IC50 values to inhibit IKr current among the above three studies, considering all three studies together, relative rank order for IKr blocking abilities is estimated as sparfloxacin > grepafloxacin = moxifloxacin ³ gatifloxacin >> levofloxacin = ciprofloxacin = ofloxacin. This agrees with our results from APD prolonging potency, namely, sparfloxacin > moxifloxacin = grepafloxacin > gatifloxacin > tosufloxacin = gemifloxacin = ciprofloxacin = trovafloxacin = sitafloxacin = levofloxacin. Another result of recent study, which reported the rank order of potency to prolong APD recorded from canine Purkinje fibres was sparfloxacin > grepafloxacin = moxifloxacin > ciprofloxacin, are also very similar to our result (13) . These agreements indicate that guinea pig ventricular myocardia, as well as canine Purkinje fiber, is a useful specimen to evaluate the APD-prolonging effects via IKr blockade.
The peak plasma concentrations after a single 400 mg oral dosing of sparfloxacin in humans ranged from 0.42 to 1.28 mg / L (equivalent to 1 to 3 mM) (4), and those of moxifloxacin ranged from 2.10 to 4.49 mg/ L (equivalent to 5 to 11 mM) (14) . The mean peak plasma concentration after the same regimen of gatifloxacin was 4.1 mg / L (equivalent to 11 mM) (15) . When the APD-prolonging fluoroquinolones are given to the patients suffering from renal or hepatic impairment, it is a concern that the plasma concentrations mentioned above may be close enough to each APD-prolonging concentration or IC50 value to block IKr current in some cases. In using some APD-prolonging fluoroquinolones for patients with predisposing factors such as pre-existing QT prolongation or electrolyte disturbance, careful monitoring would be required and concomitant administration with other APD-prolonging drugs such as antiarrhythmic agents should also be contraindicated or at least used with caution.
In conclusion, our findings clearly highlight the contrast between fluoroquinolones having no or extremely low APD-prolongation effects (levofloxacin, sitafloxacin, trovafloxacin, ciprofloxacin, gemifloxacin and tosufloxacin) and those having prominent APD-prolongation effects (gatifloxacin, moxifloxacin, grepafloxacin and sparfloxacin). These findings may account for the in vivo or clinical data that have been reported previously.
